Moleculin abstract accepted for ASCO meeting

Moleculin Biotech, Inc. has announced that an abstract detailing their research has been accepted for a poster presentation at the 2026 ASCO Annual Meeting. This acceptance signifies recognition of the company's scientific contributions within the oncology field. The presentation will offer an opportunity to share their latest findings and engage with leading experts in cancer research and treatment.